UBS Maintains Buy on Abbott Laboratories, Raises Price Target to $146
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Danielle Antalffy has maintained a Buy rating on Abbott Laboratories and increased the price target from $143 to $146.
October 17, 2024 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS has reaffirmed its Buy rating on Abbott Laboratories and increased the price target to $146, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and an increased price target by UBS suggests a positive outlook for Abbott Laboratories. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100